Rallybio Corp
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| FOR THE YEAR ENDEDDECEMBER 31, | ||
|---|---|---|
| (in thousands) | 2023 | 2022 |
| Cash Flows Used in Operating Activities: | ||
| Net loss | $(74,564) | $(66,654) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 150 | 167 |
| Net accretion of discounts/premiums on debt securities | (3,089) | (435) |
| Stock-based compensation | 10,920 | 9,499 |
| Loss on investment in joint venture | 2,041 | 1,075 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, right-of-use assets and other assets | 5,819 | (4,645) |
| Accounts payable | (99) | 487 |
| Accrued expenses and operating lease liabilities | (1,443) | 3,222 |
| Net cash used in operating activities | $(60,265) | $(57,284) |
| Cash Flows Provided by (Used in) Investing Activities: | ||
| Purchases of marketable securities | (108,414) | (201,316) |
| Proceeds from maturities of marketable securities | 138,334 | 89,500 |
| Purchase of property and equipment | (12) | (54) |
| Investment in joint venture | (2,250) | (300) |
| Net cash provided by (used in) investing activities | $27,658 | $(112,170) |
| Cash Flows Provided by (Used in) Financing Activities: | ||
| Proceeds from the issuance of common stock and pre-funded warrants upon the completion of the follow-on offering, net of underwriting discounts and commissions of $3,289 | — | 51,533 |
| Proceeds from the issuance of common stock from the stock purchase plan | 282 | 217 |
| Proceeds from the issuance of common stock from exercise of stock options | — | 21 |
| Payments of offering costs | (139) | (693) |
| Net cash provided by (used in) financing activities | $143 | $51,078 |
| Net decrease in cash and cash equivalents | (32,464) | (118,376) |
| Cash and cash equivalents—beginning of year | 56,958 | 175,334 |
| Cash and cash equivalents—end of year | $24,494 | $56,958 |
| Supplemental Disclosures of Noncash Investing and Financing Activities: | ||
| Offering costs in accounts payable and accrued expenses | $— | $139 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.